(Q34609164)

3 August 2017

1 reference

title

Novel insulin sensitizers: pharmacogenomic aspects (English)

1 reference

3 August 2017

1 reference

1 reference

Carsten Otto

1

1 reference

3 August 2017

Michael Lehrke

series ordinal

2

1 reference

3 August 2017

Burkhard Göke

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

99-116

1 reference

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A structural role for hormone in the thyroid hormone receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The RXR heterodimers and orphan receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Interdomain communication regulating ligand binding by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Role of CBP/P300 in nuclear receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A transcriptional co-repressor that interacts with nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Nuclear receptor coactivators and corepressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A signature motif in transcriptional co-activators mediates binding to nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Facilitative glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone induces GLUT4 translocation in L6 myotubes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Acute effects of troglitazone on in vivo insulin action in normal rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

In L6 skeletal muscle cells, glucose induces cytosolic translocation of protein kinase C-alpha and trans-activates the insulin receptor kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Insulin translocates PKC-epsilon and phorbol esters induce and persistently translocate PKC-beta 2 in BC3H-1 myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Insulin administration in vivo increases 1,2-diacylglycerol in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Phorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Transcriptional control of adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

21 January 2018

Regulating adipogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Control of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPAR gamma is required for placental, cardiac, and adipose tissue development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Trans-differentiation of myoblasts to adipoblasts: triggering effects of fatty acids and thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Posttranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Adipogenesis and obesity: rounding out the big picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Thiazolidinediones: a new class of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone and related compounds: therapeutic potential beyond diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator--activated receptor-gamma2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Interactions between variants in the beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.1.99

21 January 2018

Identifiers

DOI

10.1517/14622416.3.1.99

1 reference

3 August 2017

1 reference